Haleon plc Reports Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Sep 13, 2024 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, company-filing
TL;DR
Haleon bought/sold its own stock on 9/13/24. Details TBD.
AI Summary
Haleon plc announced on September 13, 2024, that it has completed a transaction involving its own shares. The filing, a Form 6-K, details this transaction as required for foreign private issuers. Specific details regarding the nature or value of the share transaction were not provided in this summary document.
Why It Matters
This filing indicates corporate activity related to Haleon's own stock, which can be a signal to investors about management's view of the company's valuation or capital allocation strategies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a share transaction by the company itself, with no immediate indication of significant financial distress or major strategic shifts.
Key Players & Entities
- Haleon plc (company) — Registrant
- DRVW 2022 Ltd (company) — Former Company Name
- September 13, 2024 (date) — Transaction Date
FAQ
What type of transaction did Haleon plc engage in regarding its own shares?
Haleon plc engaged in a 'Transaction in Own Shares' as detailed in Exhibit 99.1 of the filing.
On what date was this share transaction reported?
The transaction was reported on September 13, 2024.
What form is this SEC filing?
This is a Form 6-K, which is a Report of Foreign Private Issuer.
What was Haleon plc's former company name?
Haleon plc's former company name was DRVW 2022 Ltd.
Where is Haleon plc's principal executive office located?
Haleon plc's principal executive office is located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-13 13:52:19
Filing Documents
- a2160e.htm (6-K) — 28KB
- 0001654954-24-011907.txt ( ) — 29KB
From the Filing
IN OWN SHARES a2160e UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description          99.1  13 September 2024 - “Transaction in Own Shares”   99.1   Haleon plc:   Transaction in own shares   13 September 2024:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under its share buyback programme announced on 1 August 2024   (the "Buyback Programme").   Date of purchase: 13 September 2024 Number of Shares purchased: 510,900 Highest price paid per Share (p): 393.0000 Lowest price paid per Share (p): 387.7000 Volume weighted average price paid per Share (p): 391.4392   Following the settlement of the above, the Company's registered share capital consists of 9,119,128,372 ordinary shares. This figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/2159E_1-2024-9-13.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Sonya Ghobrial   +44 7392 784784 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562     Email:  investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .    SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 13, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary